Benzinga | Nov 1, 2021 08:46AM EDT

Chardan Capital Upgrades Evelo Biosciences to Buy, Maintains $12 Price Target

Chardan Capital analyst Keay Nakae upgrades Evelo Biosciences (NASDAQ:EVLO) from Neutral to Buy and maintains $12 price target.